Menten AI
menten.aiPioneering Generative AI for Peptide Drug Design
Health & Wellnessdrug-discoverypeptide-designgenerative-aibiotechmachine-learningpharmaquantum-simulation
About
Menten AI develops MAUD 1.0, a generative AI platform for de novo peptide macrocycle drug design targeting complex protein-protein interfaces. The platform combines generative AI with physics-based models and quantum simulations to accelerate preclinical drug discovery. It is trusted by top-10 pharma partners and backed by leading venture capital firms.
Problem
Traditional drug screening methods are slow and limited in chemical space, making it difficult to design effective peptide drugs for complex targets.
For
pharmaceutical researchers and drug discovery teams
How it works
MAUD 1.0 uses generative AI combined with physics-based models and quantum simulations to design and optimize drug-like peptide macrocycles de novo from scratch.
Business model
unknown
Status
launched
Company
Menten AI